Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1981 Sep;78(9):5685–5689. doi: 10.1073/pnas.78.9.5685

Induction of gene mutation in and cell transformation of mammalian cells by modified purines: 2-aminopurine and 6-N-hydroxylaminopurine.

J C Barrett
PMCID: PMC348828  PMID: 6946507

Abstract

2-Aminopurine, a classical mutagen in prokaryotic systems, is inactive as a carcinogen in two animal species. To determine the basis for this discrepancy in the correlation between carcinogenesis and mutagenesis, the ability of 2-aminopurine to induce somatic mutation and neoplastic transformation concomitantly in the same cellular system was examined. 6-N-hydroxylaminopurine, a related modified purine that is a mutagen and a carcinogen, was also studied. 2-Aminopurine was a mutagen in Syrian hamster embryo cells, but its activity was very weak. The maximum induced mutation frequency with either of two mutational markers was only 7 X 10(-6) mutants per surviving cell. 2-Aminopurine also induced morphological transformation of the cells under the same conditions, but the frequency was only approximately 0.04% per surviving colony. Neoplastic transformation of the cells after 2-aminopurine treatment was not observed in these experiments. These results indicate that 2-aminopurine is, at best, a weak transforming agent. The lack of carcinogenic activity in vivo with 2-aminopurine is consistent with these observations. In contrast to the results with 2-aminopurine, 6-N-hydroxylaminopurine was a very effective mutagen in these cells (up to 10(-3) mutants per survivor) and induced morphological transformation of the cells in a dose-dependent manner. Furthermore, neoplastic transformation was induced by this nucleic acid base analog. The correlation of mutagenic activity with transforming ability of these two modified purines supports a relationship between mutagenesis and carcinogenesis. However, relative to other carcinogens, there is a quantitative difference in the ability of 6-N-hydroxylaminopurine to induce cell transformation and mutation. For example, in benzo[a]pyrene-treated cultures, the ratio of the frequency of induced morphological transformation to that of somatic mutation was approximately 100, whereas for 6-N-hydroxylaminopurine-treated cultures, the ratio of transformation to mutation was only 3-12.5. This indicates that 6-N-hydroxylaminopurine is less potent than benzo[a]pyrene in inducing transformation when compared at equal mutagenic potency. This is consistent with our hypothesis that cell transformation, and possibly cancer, occurs predominantly as the result of a mutation at the chromosome level rather than a gene mutation.

Full text

PDF
5685

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barrett J. C., Bias N. E., Ts'o P. O. A mammalian cellular system for the concomitant study of neoplastic transformation and somatic mutation. Mutat Res. 1978 Apr;50(1):121–136. doi: 10.1016/0027-5107(78)90067-2. [DOI] [PubMed] [Google Scholar]
  2. Barrett J. C., Ts'o P. O. Evidence for the progressive nature of neoplastic transformation in vitro. Proc Natl Acad Sci U S A. 1978 Aug;75(8):3761–3765. doi: 10.1073/pnas.75.8.3761. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Barrett J. C., Ts'o P. O. Relationship between somatic mutation and neoplastic transformation. Proc Natl Acad Sci U S A. 1978 Jul;75(7):3297–3301. doi: 10.1073/pnas.75.7.3297. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Barrett J. C., Wong A., McLachlan J. A. Diethylstilbestrol induces neoplastic transformation without measurable gene mutation at two loci. Science. 1981 Jun 19;212(4501):1402–1404. doi: 10.1126/science.6262919. [DOI] [PubMed] [Google Scholar]
  5. Benedict W. F. Early changes in chromosomal number and structure after treatment of fetal hamster cultures with transforming doses of polycyclic hydrocarbons. J Natl Cancer Inst. 1972 Aug;49(2):585–590. [PubMed] [Google Scholar]
  6. Brockman H E, de Serres F J. Induction of ad-3 Mutants of Neurospora Crassa by 2-Aminopurine. Genetics. 1963 Apr;48(4):597–604. doi: 10.1093/genetics/48.4.597. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Cairns J. The origin of human cancers. Nature. 1981 Jan 29;289(5796):353–357. doi: 10.1038/289353a0. [DOI] [PubMed] [Google Scholar]
  8. Clive D., Johnson K. O., Spector J. F., Batson A. G., Brown M. M. Validation and characterization of the L5178Y/TK+/- mouse lymphoma mutagen assay system. Mutat Res. 1979 Jan;59(1):61–108. doi: 10.1016/0027-5107(79)90195-7. [DOI] [PubMed] [Google Scholar]
  9. Freese E. B. The mutagenic effect of hydroxyaminopurine derivatives on phage T4. Mutat Res. 1968 Mar-Apr;5(2):299–301. doi: 10.1016/0027-5107(68)90028-6. [DOI] [PubMed] [Google Scholar]
  10. Fu Y. S., Reagan J. W., Richart R. M., Townsend D. E. Nuclear DNA and histologic studies of genital lesions in diethylstilbestrol-exposed progeny. I. Intraepithelial squamous abnormalities. Am J Clin Pathol. 1979 Oct;72(4):503–514. doi: 10.1093/ajcp/72.4.503. [DOI] [PubMed] [Google Scholar]
  11. German J. Genes which increase chromosomal instability in somatic cells and predispose to cancer. Prog Med Genet. 1972;8:61–101. [PubMed] [Google Scholar]
  12. Janion C. The efficiency and extent of mutagenic activity of some new mutagens of base-analogue type. Mutat Res. 1978 Jan;56(3):225–234. doi: 10.1016/0027-5107(78)90189-6. [DOI] [PubMed] [Google Scholar]
  13. McCann J., Ames B. N. Detection of carcinogens as mutagens in the Salmonella/microsome test: assay of 300 chemicals: discussion. Proc Natl Acad Sci U S A. 1976 Mar;73(3):950–954. doi: 10.1073/pnas.73.3.950. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Ronen A. 2-Aminopurine. Mutat Res. 1980 Jan;75(1):1–47. doi: 10.1016/0165-1110(80)90026-3. [DOI] [PubMed] [Google Scholar]
  15. Sugiura K., Teller M. N., Parham J. C., Brown G. B. A comparison of the oncogenicities of 3-hydroxyxanthine, guanine 3-N-oxide, and some related compounds. Cancer Res. 1970 Jan;30(1):184–188. [PubMed] [Google Scholar]
  16. TRAININ N., KAYE A. M., BERENBLUM I. INFLUENCE OF MUTAGENS ON THE INITIATION OF SKIN CARCINOGENESIS. Biochem Pharmacol. 1964 Feb;13:263–267. doi: 10.1016/0006-2952(64)90144-3. [DOI] [PubMed] [Google Scholar]
  17. Yamamoto T., Rabinowitz Z., Sachs L. Identification of the chromosomes that control malignancy. Nat New Biol. 1973 Jun 20;243(129):247–250. doi: 10.1038/newbio243247a0. [DOI] [PubMed] [Google Scholar]
  18. de Serres F. J. Problems associated with the application of short-term tests for mutagenicity in mass-screening programs. Environ Mutagen. 1979;1(3):203–208. doi: 10.1002/em.2860010302. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES